CoChat

The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment

Open access

The DOI matches its Crossref record; 265 of the 267 references it cites were found in a registry or an index.

Abstract

Immune checkpoint inhibitors (ICI) have led to profound and durable tumor regression in some patients with metastatic cancer diseases. However, many patients still do not derive benefit from immunotherapy. Here, the accumulation of immunosuppressive cell populations within the tumor microenvironment (TME), such as myeloid-derived suppressor cells (MDSC), tumor-associated macrophages (TAM), and regulatory T cells (Treg), contributes to the development of immune resistance. MDSC and Treg expand systematically in tumor patients and inhibit T cell activation and T effector cell function. Numerous studies have shown that the immunosuppressive mechanisms exerted by those inhibitory cell populations comprise soluble immunomodulatory mediators and receptor interactions. The latter are also required for the crosstalk of MDSC and Treg, raising questions about the relevance of cell–cell contacts for the establishment of their inhibitory properties. This review aims to outline the current knowledge on the crosstalk between these two cell populations, issuing particularly the potential role of cell adhesion molecules. In this regard, we further discuss the relevance of β2 integrins, which are essential for the differentiation and function of leukocytes as well as for MDSC–Treg interaction. Lastly, we aim to describe the impact of such bidirectional crosstalk for basic and applied cancer research and discuss how the targeting of these pathways might pave the way for future approaches in immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers13020210

Cites

265 of 265 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Myeloid cell plasticity in cancer. Myeloid cell types originate from hematopoietic stem cells and multipotent immature myeloid progenitor cells in the bone marrow (BM). The differentiation toward the matured cell line (i.e., polymorphonuclear neutrophils (PMN)) is promoted by soluble mediators and chemokines. In cancer patients, the differentiation pathways are strongly affected by factors produced in the tumor microenvironment (TME) by stromal cells, immune cells, and tumor cells (e.g., granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-1β, IL-6, IL-10, IL-23, interferon-gamma (IFN-γ)). In particular, the TME promotes the polarization of macrophages toward immunosuppressive tumor-associated macrophages (TAM), which confer the inhibition of effector T cells (Teff) within the TME via various mechanisms [72]. PMN within the TME frequently show a polarization toward immunosuppressive TAN, which is driven by soluble factors such as transforming growth factor-β (TGF-β). Tumor-associated neutrophils (TAN) confer immunosuppression via multiple mechanisms. The most prominent effect of the aberrant differentiation includes the accumulation of granulocytic (G-MDSC) and monocytic (M-MDSC) myeloid-derived suppressor cells. Myeloid cells may act as an integrated system in the context of tumor immunity [49]. Depending on the structural composition of the TME, myeloid cells polarize from MDSC toward TAM or TAN or promote the tolerization of DC in the context of a nutrient-depleted, hypoxic, inflamed TME. Under normoxic conditions, IFN-γ and TNF-α have been found to reverse this polarization and promote MDSC differentiation toward immunogenic DC and inflammatory M1 macrophages. It remains questioned if MDSC and TAN undergo an irreversible polarization or can polarize to anti-tumor PMN [24].
Figure 1 Myeloid cell plasticity in cancer. Myeloid cell types originate from hematopoietic stem cells and multipotent immature myeloid progenitor cells in the bone marrow (BM). The differentiation toward the matured cell line (i.e., polymorphonuclear neutrophils (PMN)) is promoted by soluble mediators and chemokines. In cancer patients, the differentiation pathways are strongly affected by factors produced in the tumor microenvironment (TME) by stromal cells, immune cells, and tumor cells (e.g., granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-1β, IL-6, IL-10, IL-23, interferon-gamma (IFN-γ)). In particular, the TME promotes the polarization of macrophages toward immunosuppressive tumor-associated macrophages (TAM), which confer the inhibition of effector T cells (Teff) within the TME via various mechanisms [72]. PMN within the TME frequently show a polarization toward immunosuppressive TAN, which is driven by soluble factors such as transforming growth factor-β (TGF-β). Tumor-associated neutrophils (TAN) confer immunosuppression via multiple mechanisms. The most prominent effect of the aberrant differentiation includes the accumulation of granulocytic (G-MDSC) and monocytic (M-MDSC) myeloid-derived suppressor cells. Myeloid cells may act as an integrated system in the context of tumor immunity [49]. Depending on the structural composition of the TME, myeloid cells polarize from MDSC toward TAM or TAN or promote the tolerization of DC in the context of a nutrient-depleted, hypoxic, inflamed TME. Under normoxic conditions, IFN-γ and TNF-α have been found to reverse this polarization and promote MDSC differentiation toward immunogenic DC and inflammatory M1 macrophages. It remains questioned if MDSC and TAN undergo an irreversible polarization or can polarize to anti-tumor PMN [24].CC BY · PubMed Central
Figure 2 MDSC-mediated inhibition of T cell activation and proliferation. Direct inhibition of Teff involves cell–cell contacts (e.g., via checkpoint molecules), which induce proliferative arrest apoptosis, a reduced migratory activity, and attenuated T cell recirculation. T cell activation is further inhibited via soluble mediators and metabolic pathways: MDSC contribute to L-arginine and L-cysteine depletion in the TME, which causes proliferative arrest via mRNA instability of cyclin-dependent kinase 4 (cdk4), reduced phosphorylation of retinoblastoma protein (Rb), and the loss of the T cell receptor (TCR) ζ-chain on Teff. G-MDSC express high levels of NADPH oxidase (Nox)-2, mediating ROS-dependent inhibition of Teff. The cooperative activities of Nox-2, Arginase (Arg)-1, and inducible nitric oxide synthase (iNOS) generate peroxynitrite, which drives protein nitration resulting in desensitization of the TCR and the interference with IL-2 receptor signaling. The consumption of L-tryptophan and the accumulation of kynurenines in the TME add up to the inhibition of Teff and regulatory T cells (Treg) induction. CD39 and CD73 degrade extracellular ATP to adenosine, which enhances T cell inhibition and Treg induction. Indirect mechanisms of MDSC-mediated immunosuppression include the induction and expansion of Treg both via cell–cell contact-dependent mechanisms and soluble mediators (e.g., TGF-β, IL-10, prostaglandine-E2; PGE2; and A2A-receptor mediated signaling). Likewise, MDSC imprint a tolerogenic function in DC via IL-10, TGF-β, and adenosine. Both the accumulation of Treg and TAM add up to Teff inhibition within the TME. Macrophages are skewed toward an M2 phenotype via IL-10, thus impairing IL-12 production. Tumor-derived soluble factors contribute to STAT3-mediated upregulation of proteins including Nox-2, cell survival proteins (Cyclin D1), or S100A8/9, promoting MDSC accumulation (via S100A8/9 ligation to RAGE), survival, and immunosuppression.
Figure 2 MDSC-mediated inhibition of T cell activation and proliferation. Direct inhibition of Teff involves cell–cell contacts (e.g., via checkpoint molecules), which induce proliferative arrest apoptosis, a reduced migratory activity, and attenuated T cell recirculation. T cell activation is further inhibited via soluble mediators and metabolic pathways: MDSC contribute to L-arginine and L-cysteine depletion in the TME, which causes proliferative arrest via mRNA instability of cyclin-dependent kinase 4 (cdk4), reduced phosphorylation of retinoblastoma protein (Rb), and the loss of the T cell receptor (TCR) ζ-chain on Teff. G-MDSC express high levels of NADPH oxidase (Nox)-2, mediating ROS-dependent inhibition of Teff. The cooperative activities of Nox-2, Arginase (Arg)-1, and inducible nitric oxide synthase (iNOS) generate peroxynitrite, which drives protein nitration resulting in desensitization of the TCR and the interference with IL-2 receptor signaling. The consumption of L-tryptophan and the accumulation of kynurenines in the TME add up to the inhibition of Teff and regulatory T cells (Treg) induction. CD39 and CD73 degrade extracellular ATP to adenosine, which enhances T cell inhibition and Treg induction. Indirect mechanisms of MDSC-mediated immunosuppression include the induction and expansion of Treg both via cell–cell contact-dependent mechanisms and soluble mediators (e.g., TGF-β, IL-10, prostaglandine-E2; PGE2; and A2A-receptor mediated signaling). Likewise, MDSC imprint a tolerogenic function in DC via IL-10, TGF-β, and adenosine. Both the accumulation of Treg and TAM add up to Teff inhibition within the TME. Macrophages are skewed toward an M2 phenotype via IL-10, thus impairing IL-12 production. Tumor-derived soluble factors contribute to STAT3-mediated upregulation of proteins including Nox-2, cell survival proteins (Cyclin D1), or S100A8/9, promoting MDSC accumulation (via S100A8/9 ligation to RAGE), survival, and immunosuppression.CC BY · PubMed Central
Figure 3 Crosstalk of MDSC and Treg. MDSC and Treg interactions are enhanced by soluble mediators, a close metabolic cooperation, and cell–cell interactions. Particularly, MDSC-derived IL-10 and TGF-β promote Treg induction, proliferation, and activation. The secretion of TGF-β and IL-10 by Treg enhances the generation of these cytokines in MDSC, establishing a positive feedback loop. IL-10 and TGF-β promote the expression of immunosuppressive receptors (e.g., PD-L1) and enzymes (e.g., Arg-1, iNOS, and CD73) on MDSC. Autocrine IL-35 secretion by Treg, which is promoted via the PD-L1-PD-1 pathway, contributes to enhanced IL-10 secretion. The cooperative generation of adenosine (ADO) via the CD39/73 axis and the IDO-mediated accumulation of kynurenines (Kynu) further serve as important mechanisms of the bidirectional crosstalk. First, ADO prevents the maturation of MDSC via A2B-receptor (A2BR) stimulation. A2A-receptor (A2AR) stimulation augments the proliferation and immunosuppressive potential of Treg. Indoleamine-2,3-dioxygenase (IDO)-mediated depletion of tryptophan (Trp) and the Kynu accumulation in the TME add up to the induction of Treg and the recruitment of MDSC to the tumor site. Checkpoint molecules contribute to the crosstalk between MDSC and Treg via PD-L1/PD-1, CD80/CTLA-4, MHC-II/LAG-3, V domain-containing immunoglobulin suppressor of T-cell activation (VISTA)-Ligand/VISTA, Gal-9/TIM-3 (not shown), or CD155/TIGIT (not shown) interaction, promoting the suppressive activities of MDSC and Treg. Notably, CD80 expression is upregulated after direct MDSC–Treg interaction. In addition, CD40–CD40L interaction is involved in MDSC-mediated immunosuppression and Treg expansion at the tumor site. Lastly, the interaction of CD11b/CD18 on MDSC with intercellular adhesion molecule (ICAM)-1 expressed by Treg might enhance MDSC-derived ROS generation. Here, it seems plausible that the engagement of other β2 integrins might also be involved in the crosstalk between MDSC and Treg, e.g., lymphocyte function-associated antigen-1 (LFA-1) on Treg with ICAM-1 on MDSC. The inflammatory and hypoxic TME further enhances MDSC/Treg interaction via mediators, such as IL-1β, IL-6, IL-10, IFN-γ, GM-CSF, or VEGF, which enhance the secretion of IL-10 and TGF-β or promote STAT-3 signaling, contributing to the upregulation of cell surface molecules (e.g., PD-L1, CD80, Mac-1) and enzymes (CD39, Nox-2 or Arg-1) involved in the bidirectional positive feedback loops.
Figure 3 Crosstalk of MDSC and Treg. MDSC and Treg interactions are enhanced by soluble mediators, a close metabolic cooperation, and cell–cell interactions. Particularly, MDSC-derived IL-10 and TGF-β promote Treg induction, proliferation, and activation. The secretion of TGF-β and IL-10 by Treg enhances the generation of these cytokines in MDSC, establishing a positive feedback loop. IL-10 and TGF-β promote the expression of immunosuppressive receptors (e.g., PD-L1) and enzymes (e.g., Arg-1, iNOS, and CD73) on MDSC. Autocrine IL-35 secretion by Treg, which is promoted via the PD-L1-PD-1 pathway, contributes to enhanced IL-10 secretion. The cooperative generation of adenosine (ADO) via the CD39/73 axis and the IDO-mediated accumulation of kynurenines (Kynu) further serve as important mechanisms of the bidirectional crosstalk. First, ADO prevents the maturation of MDSC via A2B-receptor (A2BR) stimulation. A2A-receptor (A2AR) stimulation augments the proliferation and immunosuppressive potential of Treg. Indoleamine-2,3-dioxygenase (IDO)-mediated depletion of tryptophan (Trp) and the Kynu accumulation in the TME add up to the induction of Treg and the recruitment of MDSC to the tumor site. Checkpoint molecules contribute to the crosstalk between MDSC and Treg via PD-L1/PD-1, CD80/CTLA-4, MHC-II/LAG-3, V domain-containing immunoglobulin suppressor of T-cell activation (VISTA)-Ligand/VISTA, Gal-9/TIM-3 (not shown), or CD155/TIGIT (not shown) interaction, promoting the suppressive activities of MDSC and Treg. Notably, CD80 expression is upregulated after direct MDSC–Treg interaction. In addition, CD40–CD40L interaction is involved in MDSC-mediated immunosuppression and Treg expansion at the tumor site. Lastly, the interaction of CD11b/CD18 on MDSC with intercellular adhesion molecule (ICAM)-1 expressed by Treg might enhance MDSC-derived ROS generation. Here, it seems plausible that the engagement of other β2 integrins might also be involved in the crosstalk between MDSC and Treg, e.g., lymphocyte function-associated antigen-1 (LFA-1) on Treg with ICAM-1 on MDSC. The inflammatory and hypoxic TME further enhances MDSC/Treg interaction via mediators, such as IL-1β, IL-6, IL-10, IFN-γ, GM-CSF, or VEGF, which enhance the secretion of IL-10 and TGF-β or promote STAT-3 signaling, contributing to the upregulation of cell surface molecules (e.g., PD-L1, CD80, Mac-1) and enzymes (CD39, Nox-2 or Arg-1) involved in the bidirectional positive feedback loops.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 265 references

Cited by

See all 295

Metadata

Authors
Haist, M., Stege, H., Grabbe, S., & Bros, M.
Affiliations
Johannes Gutenberg University Mainz (DE)
Corresponding author
Haist, Maximilian
Venue
Cancers
Publisher
MDPI AG
Published
2021-01-08
Volume
13
Issue
2
Pages
210
ISSN
2072-6694 (ISSN-L)
OpenAlex
W3119068311
Cited by
295
References
267
Citations by year
2026: 100 · 2025: 69 · 2024: 42 · 2023: 35 · 2022: 32 · 2021: 17
FWCI
3.23
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Else Kröner Fresenius Foundation (TransMed Jumpstart Program: 2019_A72)
  • Deutsche Forschungsgemeinschaft (SFB_1066 (B4,B5), TR156 (B11))
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
myeloid-derived suppressor cells, regulatory T cells, tumor microenvironment, immunosuppression, immune checkpoint inhibitors, immune resistance, cell-cell crosstalk, adhesion molecules, beta2 integrins, tumor-associated macrophages, immunotherapy targets

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment. https://app.cochat.ai/papers/10.3390/cancers13020210
The paper
Haist, M., Stege, H., Grabbe, S., & Bros, M. (2021). The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment. Cancers. https://doi.org/10.3390/cancers13020210

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.